Immunotherapy of distant metastatic disease

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Schadendorf, D ^a   Algarra, S M ^b   Bastholt, L ^c   Cinat, G ^d   Dreno, B ^e   Eggermont, A M M ^f   Espinosa, E ^g   Guo, J ^h   Hauschild, A ⁱ   Petrella, T ^j   Schachter, J ^k   Hersey, P ^l  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Instituto de Oncologia Angel H Roffo   (Argentina)

^e HÔTEL DIEU   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^k The Ella Institute for Treatment and Research of Melanoma   (Israel)

^l CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

more..

Author keywords

Adoptive immunotherapy; Anti CTLA 4; Interferon; Interleukin; Metastatic melanoma; Vaccine

Indexed keywords

CANCER VACCINE;

HUMAN; IMMUNOTHERAPY; MELANOMA; METASTASIS; PATHOLOGY; REVIEW; SKIN TUMOR;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 70349575098     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp253     Document Type: Article

References (101)

1. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
2. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
4. Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921-2929.
5. Phan GQ, Attia P, Steinberg SM et al. Factors associated with response to highdose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
6. Schmidt H, Bastholt L, Geertsen P et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93: 273-278.
7. Schmidt H, Suciu S, Punt CJ et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol 2007; 25: 1562-1569.
8. Tarhini AA, Kirkwood JM, Gooding WE et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25: 3802-3807.
9. Petrella T, Quirt I, Verma S et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33: 484-496.
10. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997; 24: S24-S31.
11. Bukowski RM, Tendler C, Cutler D et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferonalpha-2b formulation. Cancer 2002; 95: 389-396.
12. Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24: 1188-1194.
13. Hauschild A, Dummer R, Ugurel S et al. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer 2008; 113: 1404-1411.
14. Spieth K, Kaufmann R, Dummer R et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol 2008; 19: 801-806.
15. Sparano JA, Fisher RI, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-1977.
16. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13: 1110-1122.
17. Hamm C, Verma S, Petrella T et al. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008; 34: 145-156.
18. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-5434.
19. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-1408.
20. Thomson DB, Adena M, McLeod GR et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-138.
21. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-811.
22. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-1751.
23. Middleton MR, Lorigan P, Owen J et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158-1162.
24. Young AM, Marsden J, Goodman A et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001; 13: 458-465.
25. Kaufmann R, Spieth K, Leiter U et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23: 9001-9007.
26. Vuoristo MS, Hahka-Kemppinen M, Parvinen LM et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res 2005; 15: 291-296.
27. Agarwala SS, Glaspy J, O'Day SJ et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-133.
28. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15: 2579-2588.
29. Johnston SR, Constenla DO, Moore J et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-1286.
30. Dorval T, Negrier S, Chevreau C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999; 85: 1060-1066.
31. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-975.
32. Hauschild A, Garbe C, Stolz W et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84: 1036-1042.
33. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-2052.
34. Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-184.
35. Ridolfi R, Chiarion-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20: 1600-1607.
36. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-6755.
37. Bajetta E, Del Vecchio M, Nova P et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006; 17: 571-577.
38. Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26: 5748-5754.
39. Davis ID, Skak K, Smyth MJ et al. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 2007; 13: 6926-6932.
40. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13: 169-183.
41. Thompson JA, Curti BD, Redman BG et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26: 2034-2039.
42. Frederiksen KS, Lundsgaard D, Freeman JA et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008; 57: 1439-1449.
43. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007; 7: 15-30.
44. Melero I, Hervas-Stubbs S, Glennie M et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
45. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-2627.
46. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007; 25: 613-631.
47. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872.
48. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007; 12: 873-883.
49. Hersh EM, Weber JS, Powderly JD et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 9022.
50. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
51. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.
52. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289.
53. Hamid O, Chin K, Li J et al. Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 9025.
54. O'Day SJ, Ibrahim R, DePril V et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 9021.
55. Wolchok JD, Ibrahim R, DePril V et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 3020.
56. Hodi FS, Hoos A, Ibrahim R et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. ASCO Annual Proceedings Part I. J Clin Oncol 2008; 26: Abstr 3008.
57. Ribas A, Antonia S, Sosman J et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: Abstr 3000.
58. Gomez-Navarro J, Antonia S, Sosman J et al. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 26: Abstr 8524.
59. Kirkwood JM, Lorigan P, Hersey P et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 9023.
60. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr LBA9011.
61. Tarhini AA, Moschos SS, Schlesselman JJ et al. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 9009.
62. Li B, Lin J, Vanroey M et al. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 2007; 125: 76-87.
63. Choi BK, Kim YH, Kang WJ et al. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 2007; 67: 8891-8899.
64. Sznol M, Hodi FS, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 3007.
65. Trikha M, Zhou Z, Nemeth JA et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004; 110: 326-335.
66. Jayson GC, Mullamitha S, Ton C et al. Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to av integrins, in patients with solid tumors. 2005 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2005; 23: Abstr 3113.
67. Cranmer LD, Bedikian AY, Ribas A et al. Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma. 2005 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2005; 24: Abstr 8011.
68. Linette G, Cranmer L, Hodi S et al. A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008: 26: Abstr 3505.
69. Mulgrew K, Kinneer K, Yao XT et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 2006; 5: 3122-3129.
70. Hersey P, Sosman J, O'Day S et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). 2005 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2005; 23: Abstr 7507.
71. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
72. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006; 12: 2337s-2341s.
73. Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: Abstr 8508.
74. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425.
75. Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20: 4169-4180.
76. Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26: 955-962.
77. Coulie PG, Karanikas V, Colau D et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10290-10295.
78. Kruit WH, Suciu S, Dreno B et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). 2008 ASCO Annual Proceedings Part I. J Clin Oncol 2008; 26: Abstr 9065.
79. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6: 404-414.
80. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8: 351-360.
81. Osada T, Clay TM, Woo CY et al. Dendritic cell-based immunotherapy. Int Rev Immunol 2006; 25: 377-413.
82. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678.
83. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-570.
84. Lesterhuis WJ, Aarntzen EH, De Vries IJ et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008; 66: 118-134.
85. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 2008; 8: 315-323.
86. Dummer R, Rochlitz C, Velu T et al. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008; 16: 985-994.
87. Heinzerling L, Burg G, Dummer R et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16: 35-48.
88. Mahvi DM, Henry MB, Albertini MR et al. Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial. Cancer Gene Ther 2007; 14: 717-723.
89. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. 2008 ASCO Annual proceedings Part I. J Clin Oncol 2008; 26: Abstr 9008.
90. Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
91. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin- Science 1984; 225: 1487-1489.
92. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321.
93. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-1166.
94. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
95. Mackensen A, Meidenbauer N, Vogl S et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 24: 5060-5069.
96. Powell DJ, Jr, Dudley ME, Hogan KA et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006; 177: 6527-6539.
97. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
98. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
99. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
100. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
101. Tran KQ, Zhou J, Durflinger KH et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008; 31: 742-751.